Orthopedics continues to lead all ASC specialties in revenue generation, with average net revenue per case increasing from $6,141 in 2023 to $6,419 in 2024. The specialty’s growth reflects rising ...
Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, targeted treatment for non-small cell lung cancer (NSCLC). The German pharma ...
MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback